ResMed Inc. (NYSE:RMD) reached a new 52-week high on Monday . The company traded as high as $70.55 and last traded at $70.38, with a volume of 308,283 shares. The stock had previously closed at $69.85.

RMD has been the topic of a number of recent research reports. Piper Jaffray Cos. downgraded shares of ResMed from an “overweight” rating to a “neutral” rating and decreased their price target for the stock from $65.00 to $57.00 in a research note on Wednesday, April 27th. Citigroup Inc. upgraded shares of ResMed from a “neutral” rating to a “buy” rating in a research note on Wednesday, April 27th. Macquarie upgraded shares of ResMed from an “underperform” rating to a “neutral” rating in a research note on Wednesday, April 27th. Zacks Investment Research downgraded shares of ResMed from a “buy” rating to a “hold” rating in a research note on Wednesday, April 27th. Finally, Needham & Company LLC restated a “hold” rating on shares of ResMed in a research note on Wednesday, April 27th. Two research analysts have rated the stock with a sell rating, eight have given a hold rating, two have assigned a buy rating and one has assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus target price of C$59.78.

The firm has a 50 day moving average of $64.59 and a 200 day moving average of $59.63. The stock has a market capitalization of $9.89 billion and a PE ratio of 28.27.

ResMed (NYSE:RMD) last posted its quarterly earnings data on Thursday, July 28th. The company reported $0.74 earnings per share for the quarter, hitting the consensus estimate of $0.74. During the same quarter in the previous year, the business earned $0.68 EPS. The firm had revenue of $518.60 million for the quarter, compared to the consensus estimate of $512.37 million. The firm’s quarterly revenue was up 14.5% on a year-over-year basis. Equities analysts anticipate that ResMed Inc. will post $2.89 earnings per share for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, September 22nd. Shareholders of record on Thursday, August 18th will be given a dividend of $0.33 per share. This represents a $1.32 annualized dividend and a yield of 1.89%. The ex-dividend date of this dividend is Tuesday, August 16th. This is a positive change from ResMed’s previous quarterly dividend of $0.30.

In other ResMed news, CEO Michael J. Farrell sold 5,975 shares of the stock in a transaction on Monday, May 16th. The stock was sold at an average price of C$57.64, for a total transaction of C$344,399.00. Following the transaction, the chief executive officer now owns 154,723 shares in the company, valued at approximately C$8,918,233.72. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider David Pendarvis sold 6,000 shares of the stock in a transaction on Friday, June 3rd. The stock was sold at an average price of C$59.41, for a total value of C$356,460.00. Following the transaction, the insider now owns 80,512 shares in the company, valued at approximately C$4,783,217.92. The disclosure for this sale can be found here.

Other hedge funds recently added to or reduced their stakes in the company. Airain ltd bought a new stake in ResMed during the fourth quarter valued at about $2,500,000. KBC Group NV raised its stake in ResMed by 36.7% in the fourth quarter. KBC Group NV now owns 43,904 shares of the company’s stock valued at $2,357,000 after buying an additional 11,795 shares during the period. TrimTabs Asset Management LLC bought a new stake in ResMed during the fourth quarter valued at about $2,189,000. Advisors Asset Management Inc. raised its stake in ResMed by 370.0% in the fourth quarter. Advisors Asset Management Inc. now owns 20,878 shares of the company’s stock valued at $1,121,000 after buying an additional 16,436 shares during the period. Finally, Marshall Wace LLP bought a new stake in ResMed during the fourth quarter valued at about $1,133,000.

ResMed Inc is engaged in the development, manufacturing, distribution and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus on sleep-disordered breathing (SDB). The Company develops various products for SDB and other respiratory disorders, including airflow generators, diagnostic products, mask systems, headgear and other accessories.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.